ClinicalTrials.gov
public full text
Public Domain
Kamlanoflast In Amyotrophic Lateral Sclerosis
This is a study of Kamlanoflast in patients with ALS. Kamlanoflast is orally administered over 24 weeks. Its effects on inflammatory and functional parameters will be studied. Information on safety and tolerability will be collected.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Creatine for the Treatment of Amyotrophic Lateral Sclerosis#869552
- Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)#896124
- Nebulized RNS60 for the Treatment of Amyotrophic Lateral Sclerosis#831814
- Use of Dalfampridine in Primary Lateral Sclerosis#1152569
- Plasmapheresis in Amyotrophic Lateral Sclerosis With Autoantibody Against NRIP#850369
Record · ID 874661
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive